Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,037 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.
Gross EE, Li M, Yin M, Orcutt D, Hussey D, Trott E, Holt SK, Dwyer ER, Kramer J, Oliva K, Gore JL, Schade GR, Lin DW, Tykodi SS, Hall ET, Thompson JA, Parikh A, Yang Y, Collier KA, Miah A, Mori-Vogt S, Hinkley M, Mortazavi A, Monk P, Folefac E, Clinton SK, Psutka SP. Gross EE, et al. Among authors: parikh a. Urol Oncol. 2023 Jan;41(1):51.e25-51.e31. doi: 10.1016/j.urolonc.2022.08.013. Epub 2022 Oct 26. Urol Oncol. 2023. PMID: 36441070 Free PMC article.
Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy.
Parikh AB, Zhong X, Mellgard G, Qin Q, Patel VG, Wang B, Alerasool P, Garcia P, Leiter A, Gallagher EJ, Clinton S, Mortazavi A, Monk P, Folefac E, Yin M, Yang Y, Galsky M, Oh WK, Tsao CK. Parikh AB, et al. Am J Clin Oncol. 2021 Mar 1;44(3):114-120. doi: 10.1097/COC.0000000000000793. Am J Clin Oncol. 2021. PMID: 33417323 Free PMC article.
Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis.
Qin Q, Jun T, Wang B, Patel VG, Mellgard G, Zhong X, Gogerly-Moragoda M, Parikh AB, Leiter A, Gallagher EJ, Alerasool P, Garcia P, Joshi H, Mbbs, Galsky M, Oh WK, Tsao CK. Qin Q, et al. Among authors: parikh ab. Discov Oncol. 2022 Aug 12;13(1):73. doi: 10.1007/s12672-022-00538-6. Discov Oncol. 2022. PMID: 35960456 Free PMC article.
Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.
Mellgard G, Patel VG, Zhong X, Joshi H, Qin Q, Wang B, Parikh A, Jun T, Alerasool P, Garcia P, Gogerly-Moragoda M, Leiter A, Gallagher EJ, Oh WK, Galsky MD, Tsao CK. Mellgard G, et al. Among authors: parikh a. J Cancer Res Clin Oncol. 2023 Jul;149(7):2833-2841. doi: 10.1007/s00432-022-04159-y. Epub 2022 Jul 5. J Cancer Res Clin Oncol. 2023. PMID: 35788726
Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data.
Martini A, Parikh AB, Sfakianos JP, Montorsi F, Galsky MD, Oh WK, Tsao CK. Martini A, et al. Among authors: parikh ab. Prostate Cancer Prostatic Dis. 2021 Sep;24(3):743-749. doi: 10.1038/s41391-021-00326-3. Epub 2021 Feb 2. Prostate Cancer Prostatic Dis. 2021. PMID: 33531652
1,037 results